Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

Aim:to study the prognostic significance of N-status,pTNM stage,EGFR (Epidermal Growth Factor Receptor), mTOR(phosphorilated on Ser2442)(mamalian Target Of Rapamycin) protein expression and p70S6 kinase(phosphorilated on Ser411)expression in operated for pulmonary carcinoid tumor patients.Material and methods:Surgically resected specimen (men n=35;women n=42, mean age 48.5±13) from 64typical carcinoid(TC) and 13atypical carcinoid(AtC) patients were studied. The N-status(N0 n=68;N1/2 n=9),pTNM stage(I n=57; II n=13;III n=7) and immunohistochemical expression of EGFR (positive n=16/negative n=61), mTOR(positive n=34/negative n=43) and p70S6(>90% n=61/£90% n=16)were evaluated.Statistical methods used:Kaplan-Meier,Wilcoxon,Cox regression analyses.Results:The 5 year survival for TCs was 88% and for AtCs–74%.The difference in mean survival time between TCs (125 months) and AtCs (72 months) was not significant(p=0.24).11% of the TCs were in N1/2 status and 15% of the AtCs were in N1/2 status. The 5 year survival for N0 was 89% and for N1/2–63% (p=0.085).The mean survival time was significantly longer in N0 status(N0-129 months,N1/2-87,p=0.005),in I and II pTNM status(I/II-125 months,III-38,p=0.005),in cases negative forEGFR (negative-128 months,positive-84,p=0.030), and in cases positive for mTOR (p=0.035). The Cox analysis confirmed the prognostic significance of N status(Hazard ratio[HR]5.25;p=0.012),pTNM stage(HR 14.14;p=0.019)and EGFR expression(HR 3.78;p=0.047).Conclusions:N0-status,pTNM I/II stage, lack of EGFRexpression and positive mTOR expression may represent favorable prognostic factors in pulmonary carcinoid tumors.

Rating:

Share or cite this content

Citations should be made in the following way:
D. Marinova, Y. Slavova, P. Titorenkov, D. Kostadinov, M. Tafradjiiska, E. Goranov, D. Petrov (Sofia, Bulgaria). Clinicopathological prognostic factors in operated for pulmonary carcinoid tumor patients. Eur Respir J 2014; 44: Suppl. 58, 515

Member's Comments

No comment yet.

Related content which might interest you: Correlation between clinical and pathological factors in resected lung carcinoid tumours Source: International Congress 2016 – Special issues in thoracic surgery Year: 2016 Primary lung sarcomas and sarcomatoid carcinomas – Clinicopathological prognostic factors in operated patients Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Evaluation of lung cancer patients with distant organ metastasis Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Clinicopathological prognostic factors in operated for small cell lung carcinoma or large cell neuroendocrine carcinoma patients Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Clinicopathological characteristics and treatment outcomes of pulmonary carcinosarcoma in eight patients Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features Year: 2015 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Prevalence of molecular changes in resected pulmonary adenocarcinomas Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Indeterminate solitary pulmonary nodule: Surgical diagnosis and models for predicting malignancy Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Significance of age, tumor location and histological subtype in lung cancer with brain metastasis Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 Survival of non small cell lung carcinoma patients with malignant pleural effusions Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Patient outcome and factors influencing lack of histology in patients with clinical diagnosis of lung cancer Source: Annual Congress 2013 –Quality management in thoracic oncology Year: 2013 Primary pulmonary sarcomatoid carcinoma: A case series Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Rare primary pulmonary tumors Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features Year: 2015 Lung cancer after lymphoma: Disease characteristics, detection methods and clinical outcome Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Clinical features and prognosis of multiple primary malignancies in patients with lung cancer Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Prognostic factors in non-small cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014